Balance Sheet
Cash Flow Statement
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginInterest Coverage RatioInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on SalesTimes Interest Earned

SAB Biotherapeutics (SABSW) EBT Margin (2021 - 2025)

SAB Biotherapeutics' EBT Margin history spans 5 years, with the latest figure at 23845.69% for Q4 2025.

  • For Q4 2025, EBT Margin rose 3251484.0% year-over-year to 23845.69%; the TTM value through Dec 2025 reached 19845.92%, up 2231520.0%, while the annual FY2024 figure was 3171.7%, 128720.0% down from the prior year.
  • EBT Margin reached 23845.69% in Q4 2025 per SABSW's latest filing, down from 27873.57% in the prior quarter.
  • In the past five years, EBT Margin ranged from a high of 27873.57% in Q3 2025 to a low of 8669.15% in Q4 2024.
  • Average EBT Margin over 5 years is 2760.71%, with a median of 104.46% recorded in 2021.
  • Peak YoY movement for EBT Margin: tumbled -796947bps in 2023, then surged 3251484bps in 2025.
  • A 5-year view of EBT Margin shows it stood at 104.46% in 2021, then tumbled by -248bps to 363.23% in 2022, then crashed by -1963bps to 7493.75% in 2023, then dropped by -16bps to 8669.15% in 2024, then skyrocketed by 375bps to 23845.69% in 2025.
  • Per Business Quant, the three most recent readings for SABSW's EBT Margin are 23845.69% (Q4 2025), 27873.57% (Q3 2025), and 15203.74% (Q2 2025).